-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Arrowhead's Plozasiran Delivers 83% Median Triglyceride Reduction In Severe hypertriglyceridemia Patients With Zero Acute Pancreatitis Events Over Two-Year Open-Label Extension Study

Benzinga·03/30/2026 07:28:06
Listen to the news
  • – Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis
  • – No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during the 2-year Phase 2b Open-Label Expansion (OLE) Study
  • – Favorable and durable improvements in atherogenic lipoproteins, including remnant cholesterol, non-HDL cholesterol, and ApoB, were observed, with a safety profile consistent with earlier trials